Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

266
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
266
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

303
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
303
Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

174
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
174
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

328
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
328
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

207
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
207
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

286
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
286

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Feasibility and signal quality of the Minder® implantable continuous EEG monitoring® system compared to 10-20 scalp electrodes over extended monitoring periods.

Epilepsia·2026
Same author

Population-Based Epidemiology of Autoimmune Seizures and Epilepsies.

Annals of neurology·2026
Same author

Duolingo-induced seizures in GAD65 IgG associated autoimmune epilepsy.

Epilepsy & behavior reports·2026
Same author

Intellectual function and psychiatric comorbidities in patients with epilepsy with eyelid myoclonia.

Epilepsy & behavior : E&B·2026
Same author

Drug-resistant glutamic acid decarboxylase 65-associated epilepsy: Pre-surgical evaluation and comparison to temporal lobe epilepsy of other etiology.

Epilepsia·2025
Same author

Clinical 7T MRI for Epilepsy: A Retrospective Review of 50 Cases.

AJNR. American journal of neuroradiology·2025

Related Experiment Video

Updated: May 22, 2025

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

8.9K

Seizures Associated with Autoimmune Disorders - Current Treatment Approaches.

Lisa Gillinder1,2, Jeffrey W Britton3

  • 1Princess Alexandra Hospital, Woolloongabba Qld, Australia.

Seminars in Neurology
|March 12, 2025
PubMed
Summary

Autoimmune-associated seizures and epilepsy, often resistant to standard treatments, may significantly improve with immunotherapy. Early diagnosis and prompt treatment are crucial for better patient outcomes.

More Related Videos

A Behavioral Screen for Heat-Induced Seizures in Mouse Models of Epilepsy
06:58

A Behavioral Screen for Heat-Induced Seizures in Mouse Models of Epilepsy

Published on: July 12, 2021

4.7K
Direct-current Stimulation and Multi-electrode Array Recording of Seizure-like Activity in Mice Brain Slice Preparation
09:39

Direct-current Stimulation and Multi-electrode Array Recording of Seizure-like Activity in Mice Brain Slice Preparation

Published on: June 7, 2016

10.4K

Related Experiment Videos

Last Updated: May 22, 2025

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

8.9K
A Behavioral Screen for Heat-Induced Seizures in Mouse Models of Epilepsy
06:58

A Behavioral Screen for Heat-Induced Seizures in Mouse Models of Epilepsy

Published on: July 12, 2021

4.7K
Direct-current Stimulation and Multi-electrode Array Recording of Seizure-like Activity in Mice Brain Slice Preparation
09:39

Direct-current Stimulation and Multi-electrode Array Recording of Seizure-like Activity in Mice Brain Slice Preparation

Published on: June 7, 2016

10.4K

Area of Science:

  • Neurology
  • Immunology
  • Epileptology

Background:

  • Autoimmune-associated seizures and epilepsy are increasingly recognized.
  • These conditions can present acutely with encephalitis or chronically with focal epilepsy.
  • They are often refractory to conventional antiseizure medications.

Purpose of the Study:

  • To review treatment strategies for autoimmune-associated seizure disorders.
  • To discuss outcomes based on underlying pathogenesis and specific autoantibodies.
  • To emphasize tailored immunotherapy for optimal patient management.

Main Methods:

  • Review of current literature and consensus opinions on treatment approaches.
  • Discussion of first-line (corticosteroids, IVIg, plasma exchange) and second-line (rituximab, cyclophosphamide) immunotherapies.
  • Analysis of relapse management and differentiation from non-inflammatory epilepsy.

Main Results:

  • Autoimmune epilepsy may respond definitively to immunotherapy, contrasting with resistance to antiseizure drugs.
  • Outcomes vary based on specific autoantibodies (e.g., anti-LGI1, anti-NMDAR) and targeted epitopes.
  • Relapses occur in up to 35% of patients, necessitating careful management.

Conclusions:

  • Early diagnosis and immunotherapy are critical for minimizing neural injury and improving outcomes in autoimmune epilepsy.
  • Treatment should be tailored based on pathophysiology, clinical context, and identified biomarkers.
  • Further definitive trials are needed to guide management, currently relying on consensus opinion.